Lavipharm (ATH:LAVI) Inventories, Finished Goods: €14.55 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATH:LAVI Lavipharm SA ATH:LAVI
82 GF Score
Price €1.64
GF Value €1.19
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Lavipharm Inventories, Finished Goods?

Lavipharm ATH:LAVI +1.11% 82 Inventories, Finished Goods is €14.55 Mil as of Dec. 2025. GuruFocus rates ATH:LAVI with a GF Score™ of 82/100 and a GF Value™ of €1.19 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Lavipharm's quarterly finished goods increased from Dec. 2024 (€10.93 Mil) to Jun. 2025 (€12.20 Mil) and increased from Jun. 2025 (€12.20 Mil) to Dec. 2025 (€14.55 Mil).

Lavipharm's annual finished goods increased from Dec. 2023 (€7.41 Mil) to Dec. 2024 (€10.93 Mil) and increased from Dec. 2024 (€10.93 Mil) to Dec. 2025 (€14.55 Mil).

Lavipharm Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Lavipharm's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lavipharm Inventories, Finished Goods Chart

Lavipharm Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only 5.04 6.14 7.41 10.93 14.55

Lavipharm Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.41 10.37 10.93 12.20 14.55
ATH:LAVI
82GF Score
Lavipharm SA ATH:LAVI
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lavipharm Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of €14.55 Mil mean?
Lavipharm (ATH:LAVI) has a Inventories, Finished Goods of €14.55 Mil as of Dec. 2025. Finished goods are inventory items that are complete and ready to be sold. View historical data on Lavipharm and its competitors.
Is Lavipharm's Inventories, Finished Goods too high?
Lavipharm's current Inventories, Finished Goods is €14.55 Mil. Overall, Lavipharm has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lavipharm's Inventories, Finished Goods compare to ZTS and UTHR?
Lavipharm's Inventories, Finished Goods of €14.55 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Drug Manufacturers company?
A good Inventories, Finished Goods depends on the Drug Manufacturers industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Lavipharm and its competitors. Lavipharm's current Inventories, Finished Goods is €14.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lavipharm stock overvalued right now?
Based on GuruFocus' analysis, Lavipharm (ATH:LAVI) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.19, compared to a current price of €1.64 — trading 37.8% above its estimated fair value. The current Inventories, Finished Goods is €14.55 Mil. Lavipharm's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Lavipharm (ATH:LAVI), the current Inventories, Finished Goods is €14.55 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lavipharm (ATH:LAVI) Overvalued in 2026?

Based on GuruFocus' analysis, Lavipharm stock appears to be overvalued. The current stock price of €1.64 is trading 37.8% above its estimated GF Value™ of €1.19. GuruFocus considers Lavipharm to be Significantly Overvalued.

Key valuation signals for ATH:LAVI:

  • Inventories, Finished Goods: €14.55 Mil
  • GF Value™: €1.19 vs. price of €1.64 (37.8% above fair value)
  • GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the ATH:LAVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lavipharm Business Description

Other Exchanges BXA0:Germany
Address 12, Agias Marinas Street, PO Box 59, Paiania, GRC, 19002
Lavipharm SA develops, manufactures, markets, and distributes pharmaceutical, cosmetic, and consumer health products in Greece and internationally. The company's product portfolio includes safe and effective therapeutic solutions that meet consumers' needs for health and well-being. Its main product categories are Cardiology, Oncology, Urology, Neurology, Psychiatry, Chronic Pain, General Medicine, Self-Treatment, and Dermocosmetic care.
82GF Score

Get the complete analysis for ATH:LAVI

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.64
Price
€1.19
GF Value